APA

Kontopodis E., Kotsakis A., Kentepozidis N., Syrigos K., Ziras N., Moutsos M., Filippa G., Mala A., Vamvakas L., Mavroudis D., Georgoulias V. & Agelaki S. (20170206). A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. : Cancer chemotherapy and pharmacology.

Chicago

Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V and Agelaki S. 20170206. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. : Cancer chemotherapy and pharmacology.

Harvard

Kontopodis E., Kotsakis A., Kentepozidis N., Syrigos K., Ziras N., Moutsos M., Filippa G., Mala A., Vamvakas L., Mavroudis D., Georgoulias V. and Agelaki S. (20170206). A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. : Cancer chemotherapy and pharmacology.

MLA

Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V and Agelaki S. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. : Cancer chemotherapy and pharmacology. 20170206.